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The HDAC6 Inhibitor Trichostatin A
Acetylates Microtubules and
Protects Axons From
Excitotoxin-Induced Degeneration in
a Compartmented Culture Model
Kelsey Hanson*, Nan Tian, James C. Vickers and Anna E. King
Wicking Dementia Research and Education Centre, College of Health, University of Tasmania, Hobart, TAS, Australia
Axon degeneration has been implicated as a pathological process in several
neurodegenerative diseases and acquired forms of neural injury. We have previously
shown that stabilizing microtubules can protect axons against excitotoxin-induced
fragmentation, however, the alterations of microtubules following excitotoxicity that
results in axon degeneration are currently unknown. Hence, this study investigated
whether excitotoxicity affects the post-translational modifications of microtubules and
microtubule-associated proteins, and whether reversing these changes has the potential
to rescue axons from degeneration. To investigate microtubule alterations, primary
mouse cortical neurons at 10 days in vitro were treated with 10 or 25µM kainic
acid to induce excitotoxicity and axon degeneration. Post-translational modifications
of microtubules and associated proteins were examined at 6 h following kainic acid
exposure, relative to axon degeneration. While there were no changes to tyrosinated
tubulin or MAP1B, acetylated tubulin was significantly (p < 0.05) decreased by 40%
at 6 h post-treatment. To determine whether increasing microtubule acetylation prior
to kainic acid exposure could prevent axon fragmentation, we investigated the effect
of reducing microtubule deacetylation with the HDAC6 inhibitor, trichostatin A. We
found that trichostatin A prevented kainic acid-induced microtubule deacetylation and
significantly (p < 0.05) protected axons from fragmentation. These data suggest that
microtubule acetylation is a potential target for axonal protection where excitotoxicity
may play a role in neuronal degeneration.
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INTRODUCTION
Axon degeneration is a pathological process that occurs in several neurodegenerative diseases, and
acquired forms of brain injury, and can occur independently of cell death (Lingor et al., 2012).
The best described mechanisms of axon degeneration are axonal pruning, which occurs during
development and Wallerian degeneration, which occurs following axon severing (Coleman, 2005;
Coleman and Freeman, 2017). In contrast, the cellular process underlying axon degeneration in a
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range of neurodegenerative diseases and following brain injury
are less well understood and are unlikely to be linked to direct
axonal severing, but rather to a gradual series of biochemical
changes following specific disease-associated pathological insults.
One such pathological insult, excitotoxicity, is a result
of excessive stimulation by the excitatory neurotransmitter
glutamate, leading to, for example, increased intracellular
calcium and a cascade of harmful calcium-dependent events
(Dong et al., 2009). Excitotoxicmechanisms have been implicated
in Alzheimer’s disease, traumatic brain injury, stroke, and
amyotrophic lateral sclerosis, which all undergo some form of
axon degeneration (as reviewed by Gibson and Bromberg, 2012;
Lai et al., 2014; Siedler et al., 2014; Lewerenz and Maher, 2015).
Our previous studies in compartmentalized cultured neurons
have shown that excitotoxicity directed to the neuronal soma
results in fragmentation of the unexposed axon (Hosie et al.,
2012). This was significantly attenuated by treatment of the
axons with the microtubule stabilizing drug, taxol, implicating
microtubule disruption in the breakdown of the axon (King et al.,
2013).
Microtubules are highly dynamic polymers of alpha and beta
tubulin. Their ability to undergo rapid changes in polymerization
state (termed dynamic instability) is essential for their function
and is controlled by the binding of associate proteins (MAPs)
as well as by their post-translational modifications (PTMs)
(Horio and Murata, 2014). The microtubule disruption that
occurs following excitotoxin exposure and leads to axon
degeneration could result from depolymerization, potentially
relating to changes to PTM or from altered MAP binding.
However, microtubule PTMs and MAP binding are not
independent, and some MAP binding capacity to microtubules
can be influenced by microtubule PTMs (Howes et al., 2014).
PTMs of microtubules include glutamylation, tyrosination,
and acetylation. Acetylation, glutamylation and detyrosination
are associated with stable microtubules, whereas tyrosination
is associated with unstable and more dynamic areas of
microtubules (Uchida and Shumyatsky, 2015). Thus, microtubule
PTMs may be a potential target for therapeutic intervention.
In this regard, drugs targeting acetylation such as HDAC6
(histone deacetylase 6) inhibitors have been investigated for the
treatment of depression, cancer, stroke, environmental stress and
Huntington’s disease (Dompierre et al., 2007; Lazo-Gómez et al.,
2013; Simoes-Pires et al., 2013; Jochems et al., 2014; Brindisi et al.,
2016, 2018; Ceccacci and Minucci, 2016; Wang et al., 2016; Rao
et al., 2017).
In this study we have investigated the temporal changes to
microtubule PTMs and MAPs following an excitotoxic insult
with a view to modifying microtubule stability to prevent axon
degeneration. Furthermore, we also investigated the effect of the
HDAC6 inhibitor, trichostatin A, on axon degeneration.
MATERIALS AND METHODS
Ethics and Mice
All experiments and procedures were approved by the University
of Tasmania Animal Ethics Committee (A12780 and A15121)
and were in accordance with the Australian Guidelines for the
Care and Use of Animals for Scientific Purposes. C57Bl/6 mice
were housed in optiMICE cages on a 12-h light/dark cycle with
free access to food and water.
Primary Cortical Cell Culture
Mouse cortical neuron cultures were prepared as previously
described (King et al., 2013). Cortical neurons were prepared
from embryonic day 15.5 (E15.5) C57Bl/6 mice. Females
were sacrificed using CO2 and embryos were removed and
decapitated. Heads were kept on ice during dissection to prevent
tissue degradation. Cortices were removed using a dissecting
microscope (Leica), dissociated from the meningeal layers and
transferred to 5ml Hanks Balanced Salt Solution (HBSS, Gibco).
Trypsin (0.0125%) was added for 4min at 37◦C, followed by
removal of HBSS and replaced with 1ml of initial plating media
[Neurobasal media (Gibco) containing 2% B27 supplement,
0.5mM glutamine, 25µM glutamate, 10% fetal calf serum and
1% antibiotic/antimiotic] and mechanically triturated with a
1ml pipette. Cell density was assessed using a trypan blue
exclusion assay and 200,000 cells were plated either into the soma
compartment of microfluidic chambers (450µm long, 10µm
wide, and 3µm high barrier grooves, Xona Microfluidics), which
allows fluidic isolation of cells from the axon (Taylor et al., 2006),
or directly into the wells of poly-L-lysine coated culture plates.
Cells were allowed to adhere to the coverslip (Livingstone) at
37◦C for 30min prior to adding initial plating media to the
chambers and were incubated at 37◦C overnight before initial
media was replacement with subsequent plating media with no
fetal calf serum and glutamate. Cells were grown to 10 days in
vitro (DIV) at 37◦C in 5% CO2.
Pharmacological Manipulation
Cells were treated with 0, 10, or 25µM of kainic acid (Sigma,
lot #SLBD1491V) in DMSO (Sigma, Lot # RNBF1056) at 10
DIV, a timepoint which corresponds to dense axonal growth in
the axon compartment of microfluidic chambers (Hosie et al.,
2012; Millet and Gillette, 2012). Cells in 12-well plates or the
soma compartment of microfluidic chambers were exposed to
kainic acid for 1, 6, and 18 h. For a set of experiments cells
were treated with trichostatin A, an inhibitor of the deacetylating
enzyme HDAC6, which promotes microtubule acetylation.
Cells at 10 DIV in 12-well plates or axonal compartment
of microfluidic chambers were treated with 10 or 100 nM
trichostatin A (Sigma, Lot # 026M4036V) for 2 h before 6 h
of kainic acid exposure prior to ELISA analysis for acetylated
tubulin. The health of cells following TSA treatment was
not significantly different from vehicle control, as determined
using an alamarBlue assay (Supplementary Figure 1). For all
pharmacological manipulations vehicle controls were performed
and are reported. No significant difference was found in any
measure for vehicles to untreated cells.
Live Cell Imaging and Quantitation of
Axonal Degeneration
Microfluidic cultures were imaged on a Nikon TiE live cell
microscope, with chambers maintained at 37◦C. Imaging was
performed prior to treatment and 18 h following treatment.
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Axonal side of the microfluidic chambers were imaged using 40×
objective lens to measure axon fragmentation and degeneration.
A quantitative measure of axonal degeneration was obtained
from five random regions of interest (200 × 200µm) in the
axonal chamber, at least 40µm away from the microgrooves.
Identical regions were imaged before and after treatment. Axon
degeneration was calculated by counting degenerated axons.
A degeneration index (DI) was determined by the following
equation.
DI =


(
axons degenerated before
axons degenerated after
)
total number of axons

× 100 (1)
The percentage fragmentation refers to the percentage of axons
the have fragmented after treatment, compared to the total
number of axons before treatment. In our experiments we also
analyzed 35, 50, and 100µM of kainic acid in the cell culture
using live imaging, however the axons were too degenerated to
be able to target therapeutically.
ELISA Analysis of Microtubule
Post-translational Modifications
Plating media was removed from cells plated in 12-well trays,
and cultures were rinsed with HBSS. Cells were harvested with
RIPA buffer with protease (CompleteTM Mini Protease Inhibitor
Cocktail tablets, Roche) and phosphatase inhibitors (Phosphatase
Inhibitor Cocktail, A.G. Scientific). Samples were centrifuged at
13,000 rpm for 1min and pellets were discarded. Samples were
diluted at 1:300 in 50 µl bicarbonate/carbonate coating buffer
(AbCam), added to 96-well plate and incubated overnight at 4◦C.
For the standard curve, protein samples were serially diluted at
1:100, 1:200, 1:400, and 1:800. A blank and no primary control
were included to correct for ELISA results. Plate was washed
with washing buffer (0.01M PBS with 0.05% tween-20) prior to
blocking with blocking buffer (0.01M PBS with 5% fetal bovine
serum) and incubated at 37◦C for 30min. Plates were washed
prior to incubation with detecting antibodies (acetylated tubulin
1:500 mouse, Sigma; tyrosinated tubulin 1:500 rabbit, Millipore;
tau 1:1,000 rabbit, DAKO; CRMP2 1:1,000 rabbit, Sigma; MAP1B
1:500 mouse, AbCam) diluted in blocking buffer for 1 h at room
temperature. Plates were washed and incubated with species-
specific HRP secondary antibody (DAKO) diluted in blocking
buffer at 1:2,000 and incubated at room temperature for 45min.
Plates were washed and incubated with room temperature
tetramethylbenzidine (TMB) substrate (Thermo Scientific, Lot #
SA2328991) for 15min. The reaction was stopped 0.1M H2SO4.
Plate was read using plate reader at 450 nm.
Western Blot Analysis of Microtubule
Post-translational Modifications
Plating media was removed from microfluidic chambers and
culture was rinsed with HBSS. Axons were harvested with
RIPA buffer with protease (CompleteTM Mini Protease Inhibitor
Cocktail tablets, Roche) and phosphatase inhibitors (Phosphatase
Inhibitor Cocktail, A.G. Scientific), with protein pooled from
2 to 4 chambers per treatment group. Denatured protein
samples (20 µg) were electrophoresed into Bolt R© 4–12%
Bis-Tris gels (Invitrogen), transferred to PVDF membrane
(Bio-Rad) and incubated overnight with primary antibodies
acetylated tubulin (1:1,000 mouse, Sigma), tyrosinated tubulin
(1:1,000 rabbit,Millipore),MAP1B (1:1,000mouse, AbCam). The
corresponding anti-rabbit or anti-mouse horseradish peroxidase
conjugated secondary antibody (1:7,000, DAKO) was used as
previously described (King et al., 2018). GAPDH (1:5,000
mouse, Millipore) was used as a loading control. Bands were
visualized with enhanced chemiluminescence (ECL) solution-
Luminata ForteWestern horseradish peroxidase (HRP) substrate
(Millipore) and images acquired with a Chemi-Smart 5000
Imaging System (Vilber Lourmat) equipped with Chemi-Capt
5000 software. Band intensity was measured as the integrated
intensity using Fiji software. After standardizing to GAPDH,
each value was calculated as a percentage of control samples (See
Supplementary Figure 1).
Statistical Analysis
Values were reported as means ± standard error of the mean
(SEM), with differences considered significant at p < 0.05.
Differences for ELISA and axon degeneration counts were
evaluated using one-way ANOVA, with Tukey’s post-hoc test
for multiple comparisons between groups. For kainic acid live
imaging experiments two coverslips on five separate culture days
were analyzed. For trichostatin A live imaging experiments, 1–
2 coverslips from four separate culture days were analyzed. For
whole cell kainic acid ELISAs, three coverslips per treatment from
four separate culture days were used. For whole cell trichostatin A
ELISAs, three coverslips per treatment from five separate culture
days were used. For axon-only kainic acid ELISAs, cells were
pooled from 2 to 3 chambers per treatment from four separate
culture days. For axon-only trichostatin A ELISAs, cells were
pooled from 2 to 3 chambers per treatment from five separate
culture days. All statistical analysis and graphs were prepared in
GraphPad Prism (v6.1).
RESULTS
Model of Excitotoxin-Induced Axon
Degeneration
Microfluidic chambers allow compartmentalized separation of
axons from the somatodendritic compartment, which permits
treatment to be applied exclusive to either compartment of
the chamber. To establish an acute model of excitotoxin-
induced axon degeneration, mouse cortical neurons at 10
DIV were exposed to 10 and 25µM kainic acid in the
somatodendritic compartment for 18 h. Live imaging of axons
was performed immediately prior to and post-treatment to
determine a degeneration index. Axon loss was significantly
increased (p < 0.05) at 25µM kainic acid compared to control
(Figure 1A). Axonal degeneration at both 10 and 25µM kainic
acid was significantly increased (p < 0.05) compared to control
(Figure 1B).
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FIGURE 1 | Axon degeneration and loss in microfluidic chambers after kainic acid treatment. Live imaging of the axonal compartment of microfluidic chambers were
analyzed for (A) axon loss and (B) axon degeneration index after treatment with 10 or 25µM kainic acid. Axon loss was significantly increased (p < 0.05) following
25µM kainic acid treatment relative to control, whereas, 10µM kainic acid did not cause significant axon loss compared to control. The axon degeneration index was
significantly increased (p < 0.05) following either 10 or 25µM doses of kainic acid compared to control. Bar graph represents mean ± SEM *p < 0.05 relative to
control.
Microtubule Alterations After
Excitotoxin-Induced Axon Degeneration
We next determined whether there were changes in microtubule
PTMs and the microtubule-associated protein, tau, following
25µM kainic acid exposure at 1 and 6 h, and whether these
changes were related to downstream degeneration (Figure 2).
Neuronal cells grown on 12-well trays and cells grown in the
somatodendritic compartment of microfluidic chambers were
exposed to 25µM kainic acid for 6 h. ELISA analysis of neurons
demonstrated that, at 1 h after 25µM kainic acid treatment,
acetylated and tyrosinated tubulin levels were unchanged,
however the microtubule associated protein tau was significantly
(p < 0.05) increased, compared to control (Figures 2A–C).
At 6 h after 25µM kainic acid treatment in both neurons
and axons, acetylated tubulin levels were significantly (p <
0.05) decreased (Figure 2D). Tyrosinated tubulin levels were
unchanged (Figure 2E), whereas, tau levels were also significantly
(p < 0.05) increased (Figure 2F). Western blot analysis of
acetylated tubulin levels in axons confirmed these were also
significantly (p < 0.05) decreased (Figure 2G).
Since 25µM kainic acid treatment affected levels of the
microtubule associated protein tau, we examined whether
other microtubule associated proteins were altered at 6 h post
treatment. Neuronal cells grown on 12-well trays and cells grown
in somatodendritic compartment of microfluidic chambers were
exposed to 25µM kainic acid for 6 h. CRMP2 and MAP1B
levels in neurons and axons were examined using ELISA. Like
tau, CRMP2 was significantly (p < 0.05) increased following
excitotoxicity (Figures 3A,C) and MAP1B was unchanged in
both neurons and axons (Figures 3B,D).
Trichostatin A and Microtubule Alterations
Since our data showed significantly reduced acetylated tubulin
levels in the axon after 25µM kainic acid treatment (Figure 2),
we hypothesized that promoting microtubule acetylation could
rescue these changes and prevent axon degeneration. To promote
microtubule acetylation, trichostatin A was used to inhibit the
de-acetylating enzyme HDAC6.
We first determined the concentrations of trichostatin A
required to promote acetylation in our primary mouse cortical
cultures. ELISA analysis demonstrated that acetylated tubulin
levels after 10 and 100 nM trichostatin A were significantly (p
< 0.05) increased compared to control at 2 h post-treatment
(Figure 4A).
We next determined whether HDAC6 inhibition with
trichostatin A could rescue acetylated tubulin following
excitotoxin exposure. Neuronal cells grown on 12-well trays and
the axonal compartment of microfluidic chambers were pre-
treated with low (10 nM) trichostatin A for 2 h prior to exposure
to 25µM kainic acid. ELISA analysis demonstrated that 10 nM
trichostatin A restored acetylated tubulin levels after kainic acid
exposure, as compared to control, in both neurons and axons
(Figures 4B,C). Western blot analysis also demonstrated that
10 nM trichostatin A restored acetylated tubulin levels after
excitotoxicity in axons (Figure 4D).
Since our results had shown that tau and CRMP2 levels were
increased by kainic acid, we examined the effect of trichostatin
A on these MAPs. ELISA analysis of neurons demonstrated that
10 nM trichostatin A treatment restored tau to control levels in
the presence of kainic acid (Figure 5B). However, CRMP2 levels
remained significantly (p < 0.05) higher following kainic acid
in the presence of 10 nM trichostatin A (Figure 5D). As we had
previously shown, tyrosinated tubulin and MAP1B levels were
unaffected by kainic acid and these were also unchanged at 10 nM
trichostatin A treatment (Figures 5A,C). ELISA analysis of axons
also demonstrated that tau levels were restored after 10 nM
trichostatin A, and tyrosinated tubulin levels were unchanged
(Figures 5E,F).
Trichostatin A and Axon Degeneration
We next determined if the rescue of acetylation by trichostatin
A treatment following excitotoxin exposure was also protective
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FIGURE 2 | Changes to microtubules after kainic acid treatment. Changes to microtubule post-translational modifications and the microtubule-associated protein tau
were investigated in both whole cultured neurons and isolated axons after treatment with 25µM kainic acid. ELISA analysis of neurons at 1 and 6 h after 25µM kainic
acid treatment showed (A) a significant decrease (p < 0.05) in acetylated tubulin levels after 6 h and (B) a significant decrease (p < 0.05) in tau levels at both 1 and
6 h, relative to control. (C) Tyrosinated tubulin levels were unchanged compared to control. ELISA analysis of axons at 6 h post treatment with 25µM kainic acid
demonstrated (D) significantly decreased (p < 0.05) levels of acetylated tubulin, whereas (E) tau axonal levels were significantly increased (p < 0.05) at this timepoint
relative to control. Axonal levels of (F) tyrosinated tubulin were unchanged compared to control. To confirm the effect of 25µM kainic acid on acetylated tubulin in
axons Western blot analysis was performed (G) demonstrating a significant decrease (p < 0.05). Bar graph represents mean ± SEM *p < 0.05 relative to control.
against axonal degeneration (Figure 6). Neurons were grown in
microfluidic chambers and axons exposed to low (10 nM) and
high (100 nM) trichostatin A for 2 h prior to somatodendritic
treatment with 25µM kainic acid. Axon degeneration was
quantitated from images acquired before and 18 h after kainic
acid treatment. In the presence of 10 and 100 nM trichostatin A,
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FIGURE 3 | Changes to microtubules associated proteins after kainic acid treatment. Microtubule-associated proteins, CRMP2 and MAP1B levels were analyzed in
neurons and axons after 25µM kainic acid treatment for 6 h. ELISA analysis demonstrated that CRMP2 levels in (A) neurons and (C) axons were significantly
increased (p < 0.05) relative to control. ELISA analysis of MAP1B levels in (B) neurons and (D) axons were unchanged compared to control after 25µM kainic acid
treatment. Bar graph represents mean ± SEM *p < 0.05 relative to control.
axon degeneration (Figure 6B) and axon loss (Figure 6A) were
significantly reduced (p < 0.05) after exposure to 25µM kainic
acid.
DISCUSSION
Understanding the mechanisms underlying the relationship
between microtubule alterations and axon degeneration can
potentially lead to a better understanding of neurodegenerative
changes linked to excitotoxicity. The current study
investigated whether excitotoxin-induced axon degeneration
caused alterations in the post-translational modifications
of microtubules and the expression of microtubule-
associated protein, tau, and whether inhibition of these
biochemical changes to these cytoskeletal proteins can protect
axons.
The main finding of this study was that, following excitotoxin
exposure, there were changes to both microtubule PTMs and to
the levels of MAPs expressed by neurons and that these changes
occurred within 6 h of treatment. The key change to PTMs was
the acetylation of tubulin which occurred by 6 h and was present
in both whole neuron analysis as well as within the axons. The
major enzyme involved in tubulin acetylation state in mammals
is alpha-tubulin acetyltransferase 1 (αTAT1; Coombes et al.,
2016). It is currently unclear whether loss of tubulin acetylation
in the current project results from increased deacetylation or
from decreased acetylation. Furthermore, downstream processes
following kainic acid exposure that result in loss of acetylation
are currently not known but will be the subject of future
investigations.
In the current study, treatment with trichostatin A prevented
decreases in acetylated tubulin levels after kainic acid exposure,
consequently reducing axonal fragmentation and axon loss,
suggesting that tubulin deacetylation is a key event in excitotoxin
induced axon degeneration. Trichostatin A is a HDAC6 inhibitor,
which has been investigated in motor neuron degeneration
(Yoo et al., 2011; Lazo-Gómez et al., 2013) and used to
treat retinal degenerative diseases (reviewed in Zhang et al.,
2015). The importance of acetylation in microtubule stability
has been widely reported (Howes et al., 2014; Portran et al.,
2017). It is known that acetylated tubulin protects microtubules
against mechanical aging and is also a marker of long-lived
microtubules (Portran et al., 2017). Increasing microtubule
acetylation using trichostatin A, has been shown to restore
axonal transport in rat cortical neurons, following exposure
to mutant leucine-rich repeat kinase (LRRK2) (Godena et al.,
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FIGURE 4 | Effect of trichostatin A on microtubule acetylation following kainic
acid treatment. Acetylated tubulin levels in whole cultured neurons were
(Continued)
FIGURE 4 | analyzed after 10 and 100 nM of trichostatin A treatment for 2 h.
(A) ELISA analysis of acetylated tubulin levels after 10 or 100 nM trichostatin A
demonstrated a significant increase (p < 0.05) compared to control. ELISA
analysis demonstrated that in (B) whole cultured neurons and (C) isolated
axons, 10 nM trichostatin A inhibited the effect of 25µM kainic acid on
acetylated tubulin levels, and the levels of acetylated tubulin levels in kainic
acid treated neurons which had been treated with trichostatin A were not
significantly different from control, despite the significant decrease (p < 0.05) in
acetylated tubulin in cells treated with kainic acid alone. (D) To confirm the
ELISA analysis of acetylated tubulin levels a Western blot was performed of
harvested isolated axons from neurons treated with 25µM kainic acid in the
presence of absence of axonal trichostatin A (10 nM). This confirmed that
trichostatin A rescued the decrease in acetylation resulting from kainic acid
treatment. Bar graph represents mean ± SEM *p < 0.05 relative to control.
TSA, trichostatin A; KA, kainic acid.
2014). The same study showed that in vivo, trichostatin A
treatment or knockdown of HDAC6 and Sir-related protein
(SIRT) 2 (Sirt2), rescued axonal transport in a Drosophila
model of mutant LRRK2. In cultured mouse cerebellar granule
cells, levels of acetylation were compared between Wallerian
degeneration slow (WldS) mice, which have a mutation
that slows Wallerian degeneration (Lunn et al., 1989) and
wildtype mice (Suzuki and Koike, 2007). The authors found
that base levels of acetylation were increased in WldS cells
compared to wildtype. Furthermore, the authors showed that
the deacetylating enzyme SIRT2 plays a key role in resistance of
WldS cells to axon degeneration, whereby they found decreased
SIRT2 in WldS granule cell cytoplasm. Additionally, SIRT2
knockdown enhanced microtubule acetylation and reduced axon
degeneration in wildtype granule cells. These findings also
highlight the importance of microtubule acetylation in axon
degeneration.
Our study also showed that tyrosinated tubulin is unchanged
following kainic acid exposure. In contrast to acetylation,
which is associated with long-lived microtubules, tyrosination
is present in highly dynamic microtubules at the proximal end
of the axon (Witte et al., 2008), and has been reported as a
destabilizing microtubule PTM (Kreis, 1987; Khawaja et al.,
1988). This suggests that destabilizing microtubules through
tyrosination is not the key factor in driving excitotoxin-
induced axon degeneration. However, in axon regeneration
studies, absence of tubulin tyrosine ligase, which promoted
tubulin tyrosination, has been shown to severely reduce
axon regeneration (Song et al., 2015), suggesting that tubulin
tyrosination may be more important for regeneration rather
than degeneration. However, PTMs have also been described
following developmental axon pruning, which can be modeled
in vitro by trophic factor withdrawal (reviewed in Saxena and
Caroni, 2007). Developmental axon pruning has been shown to
involve decreases in both acetylation and tyrosination, with an
accompanying increase in detyrosinated tubulin (Unsain et al.,
2018).
The microtubule-associated protein, tau, has been implicated
in neurodegenerative disease, particularly Alzheimer’s disease
(AD) and was therefore of interest in this study. In AD, tau
has been reported to dissociate from microtubules; thereby
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FIGURE 5 | Effect of trichostatin A on tyrosinated tubulin and microtubule-associated proteins following kainic acid treatment. ELISA analysis demonstrated that (A)
trichostatin A had no effect on neuronal tyrosinated tubulin levels following kainic acid treatment relative to control. (B) Trichostatin A rescued kainic acid-induced
increases in tau, with no significant difference in tau levels for kainic acid treated cells in the presence of trichostatin A. (C) MAP1B levels were unchanged compared
to control with any of the treatments. (D) CRMP2 levels were significantly increased (p < 0.05) relative to control by either treatment with kainic acid or trichostatin A or
by kainic acid in the presence of trichostatin A. Tyrosinated tubulin and tau levels were also analyzed in isolated axons after treatment of the neurons with 25µM kainic
acid in the presence or absence of axonal 10 nM trichostatin A. (E) Tyrosinated tubulin levels were not significantly different between treatment groups. (F) As
expected, tau levels were significantly increased (p < 0.05) after 25µM kainic acid treatment, compared to control and this effect was prevented by trichostatin A
treatment. Bar graph represents mean ± SEM *p < 0.05 relative to control. TSA; trichostatin A, KA; kainic acid.
Frontiers in Neuroscience | www.frontiersin.org 8 November 2018 | Volume 12 | Article 872
Hanson et al. Trichostatin A Protects Axons From Degeneration
FIGURE 6 | Axon degeneration and axon loss after kainic acid treatment in the presence of trichostatin A. Live images of the axonal compartments of microfluidic
chambers were analyzed for (A) axon loss and (B) axon degeneration after treatment of the neurons with 25µM kainic acid in the presence or absence of 10 or
100 nM axonal trichostatin A. Both axon loss and axon degeneration were significantly increased (p < 0.05) with 25µM kainic acid treatment, however, this effect was
rescued by treatment with either concentration of trichostatin A. In the presence of trichostatin A, axonal loss and degeneration were not significantly different from
controls. (C) Figure to show how trichostatin A and kainic acid treatment is administered to microfluidic chamber compartments. Representative images for (D)
control, (E) 25µM kainic acid, (F) 10 nM trichostatin A + 25µM kainic acid and (G) 100 nM trichostatin A + 25µM kainic acid. Bar graph represents mean ± SEM *p
< 0.05 relative to control. Scale bar = 50µm. TSA, trichostatin A; KA, kainic acid.
reducing microtubule stability (Sontag et al., 1996; Kadavath
et al., 2015). The dissociated tau then aggregates to form tau
neurofibrillary tangles; a major hallmark of Alzheimer’s disease.
However, the exact function of tau in binding to microtubules
is not clear. In this study, we showed that tau expression levels
were increased following excitotoxicity. Tau was shown to be
increased as early as 1 h after kainic acid treatment, suggesting
it could be a compensatory mechanism, potentially to increase
microtubule stability. The changes in tau prompted us to examine
expression levels of other MAPs and we demonstrated that like
tau, CRMP2 was increased following excitotoxin exposure. The
dysregulation and hyperphosphorylation of CRMP2 has been
observed in Alzheimer’s disease (Williamson et al., 2011; Hensley
and Kursula, 2016). Examining phosphorylation of these MAPs
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as well as how these proteins are altered by excitotoxic treatment,
will be of interest in future studies.
Alterations to microtubules have also been demonstrated in
other forms of axonal injury. For example, dynamic stretch
injury of neuronal cultured cells induced axon degeneration,
which was inhibited by taxol (Tang-Schomer et al., 2010).
This strengthens earlier research in this area, suggesting that
cytoskeletal changes begin as early as 5min post fluid percussive
injury (Pettus and Povlishock, 1996), indicating that changes to
microtubules could be one of the earliest events to occur after
initiating axonal injury and degeneration. Another study which
investigated alpha tubulin levels after optic nerve stretch injury
found decreased alpha tubulin levels between 0.5 and 4 h post-
injury, and a secondary decline after 72 h post-injury (Serbest
et al., 2007). This also suggests that microtubules may have an
initial role after injury and another role in a secondary event
post-injury.
CONCLUSION
Together these data indicate that alterations to microtubule
may be an early and modifiable event in several forms
of axon degeneration. The earliest change detected, after
1 h of kainic acid treatment, was a significant increase in
tau, which was followed by 6 h by a significant decrease in
acetylated tubulin and significant increase in CRMP2. These
MAPs and PTM are associated with dynamic instability
of the microtubules, however tyrosinated tubulin, and
MAP1B levels, which are also linked to microtubule
stability were unaffected. Together these results suggest
that microtubule alterations were specific to the insult.
Promotion of microtubule acetylation with trichostatin A
treatment, in some cases restored altered levels of PTMs and
MAPs to control levels. The current study demonstrates
that altering microtubule acetylation can help prevent
axon degeneration through excitotoxin exposure. Further
deciphering microtubule post-translational modifications and
their interaction with degenerating pathways will be important
in providing therapeutic treatment in several neurodegenerative
diseases.
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